NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Acadia Pharmaceuticals Inc. (ACAD) Stock Analysis

Acadia Pharmaceuticals Inc. (ACAD) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

ACAD

$20.19

−$0.25 (−1.22%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare ACAD with… →

ACAD Key Statistics

As of Oct 21, 2026
Trading
Open
$20.44
Previous Close
$20.44
Day's Range
20.10–20.54
52-Week Range
18.39–30.96
Volume
1.41M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.89
Valuation
Market Cap
$3.48B
P/E Ratio
9.05
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
21.93
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
50.86
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
3.06
EPS (ttm)Profit attributable to each share over the last twelve months.
2.23
Financials (FY)
Revenue (FY)
$1.07B+11.87%
Net Income (FY)
$391.00M+72.66%
Profit marginThe share of revenue left as profit after all costs and taxes.
33.42%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
172.31M
1-Year Return
−5.08%
Dividend and dates
Earnings Date
November 4, 2026estimated
Avg Volume
1.86M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, ACAD closed at $20.19, −5.08% over 1 year.

Acadia Pharmaceuticals Inc. (ACAD) has a market capitalization of $3.48B.

In fiscal 2025, ACAD reported revenue of $1.07B.

ACAD Stock Return by Calendar Year

Acadia Pharmaceuticals Inc. (ACAD) 10-year return: what $10,000 became

1 year
$10,000 $9,492
−5.08%
5 years
$10,000 $11,186
+11.86%
10 years
$10,000 $7,968
−20.32%

If you had invested $10,000 in Acadia Pharmaceuticals Inc. (ACAD) 10 years ago, at the close on October 21, 2016, it would have been worth $7,968 at the close on October 21, 2026: −20.32% in total, −2.25% a year. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−24.41%
2025+45.56%
2024−41.39%
2023+96.67%
2022−31.79%
2021−56.34%
2020+24.96%
2019+164.56%
2018−46.30%
2017+4.40%
2016 (partial year)−18.14%

As of October 21, 2026.

ACAD Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$1.07B$391.00M36.5%
2024$957.80M$226.45M23.6%
2023$726.44M−$61.29M−8.4%
2022$517.24M−$215.98M−41.8%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$1.07B$982.51M$104.81M$391.00M36.5%
2024$957.80M$875.96M$84.28M$226.45M23.6%
2023$726.44M$684.80M−$73.38M−$61.29M−8.4%
2022$517.24M$507.07M−$223.60M−$215.98M−41.8%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

ACAD Valuation vs Biotechnology Median

Median of 608 stocks
MetricACADBiotechnology medianvs median
P/E9.0516.6045% below
P/S ratio3.0613.300.2x the median
Profit margin33.42%−38.31%71.7 pts above

Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Acadia Pharmaceuticals Inc. (ACAD) is capitalised at $3.48B on the latest close. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 796.

ACAD last closed at $20.19 on October 21, 2026. That is −$0.25 (−1.22%) against the previous close. The 52-week range on file runs from $18.39 to $30.96. The latest close sits 9.79% above that 52-week low.

Financial Health

In fiscal 2025, Acadia Pharmaceuticals Inc. reported revenue of $1.07B. That is +11.87% against the prior fiscal year, when revenue was $957.80M. Net income for the same year was $391.00M. That is +72.66% against the prior fiscal year. The reported profit margin is 33.42%. That is 71.7 percentage points above the Biotechnology median of −38.31%. Trailing earnings per share are 2.23.

Across the 4 fiscal years on file, revenue moves from $517.24M in 2022 to $1.07B in 2025. Of those 4 years, 2 report positive net income.

Valuation Assessment

ACAD trades at a trailing price-to-earnings ratio of 9.05. That is 45.48% below the Biotechnology median of 16.6. On forward earnings the ratio is 21.93. The PEG ratio, which sets the P/E against expected earnings growth, reads 50.86. Measured against sales, the shares trade at 3.06 times revenue. On price-to-sales that is 0.2 times the Biotechnology median of 13.3. 608 Biotechnology companies report these metrics, and the medians quoted come from that group.

Beta against the wider market is reported at 0.89. Daily returns over the trailing 10 years annualize to a volatility of 61.8%. The trailing one-year total return is −5.08%. Across 10 years the annualized return works out at −2.25%.

Growth & Income

No dividend is on file for ACAD.

Across the complete calendar years on file, 2019 returned +164.56% and 2021 returned −56.34%. Of the 9 complete calendar years on file, 5 finished higher. 2026 is still running; the total return is −24.41% year to date.

Peer Comparison

Acadia Pharmaceuticals Inc. (ACAD) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Acadia Pharmaceuticals Inc. ACAD $3.48B 9.1
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Acadia Pharmaceuticals Inc. trades at a P/E of 9.1.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Acadia Pharmaceuticals Inc.

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America. The company offers NUPLAZID (pimavanserin), a selective serotonin inverse agonist/antagonist for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 to treat the symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function. It also develops remlifanserin, which is in phase 2 clinical trial for the treatment of alzheimer's disease psychosis and lewy body dementia psychosis; ACP-211, which is in phase 2 clinical trial to treat major depressive disorder; ACP-711, which is in phase I clinical trial for the treatment of essential tremor; and ACP-271, a GPR88 agonist for the treatment of tardive dyskinesia and huntington's disease and is in phase I trial. In addition, the company develops ACP-2591, a cGP analogue which is in Phase 1 clinical trial to treat rett syndrome and fragile X syndrome; and STOKE Antisense Oligonucleotide Program, which is in discovery program for SYNGAP1 syndrome. It has a license agreement with Neuren Pharmaceuticals Limited to trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop, and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.

Visit website →